Welcome to our dedicated page for GILEAD SCIENCES SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences Chief Medical Officer Dietmar Berger reported routine equity compensation activity. On June 10, 2026, he exercised 533 restricted stock units, converting them into the same number of Gilead common shares at an exercise price of $0.00 per share.
To cover associated tax obligations, 263 common shares were disposed of at $121.48 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 19,252 shares of common stock and 46,928 restricted stock units, which continue to vest over a four-year schedule.
Gilead Sciences EVP and General Counsel Keeley M. Cain Wettan reported routine equity compensation activity. On June 10, 2026, 589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share.
On the same date, 283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations tied to this equity event. After these transactions, the insider directly holds 5,360 shares of common stock and 19,997 restricted stock units, which vest over a four-year schedule.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported routine equity compensation activity. On June 10, 2026, he exercised restricted stock units covering 2,796 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations, 1,341 shares of common stock were disposed of as a tax-withholding transaction at $121.48 per share, rather than through an open-market sale. Following these transactions, he holds 174,646 shares of Gilead common stock directly and 27,851 restricted stock units, which vest over a four-year schedule.
Gilead Sciences, Inc. reported that Johanna Mercier, Chief Communications & Corporate Affairs Officer, exercised restricted stock units on June 10, 2026, converting 2,796 RSUs into the same number of common shares at a stated price of 0.00 per share. Each RSU represents the right to receive one share of common stock and follows a 4-year vesting schedule.
On the same date, 1,341 common shares were disposed of in a tax-withholding transaction at 121.48 per share. Following these transactions, she directly holds 127,234 shares of Gilead common stock and has 27,851 restricted stock units outstanding.
Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported the vesting and settlement of 8,779 restricted stock units into an equal number of common shares on June 10, 2026. In connection with this vesting, 4,213 shares of common stock were withheld at $121.4800 per share to satisfy tax obligations. Following these transactions, he directly held 622,133 shares of Gilead common stock, and 92,080 restricted stock units were reported as outstanding.
Gilead Sciences Chairman & CEO Daniel O'Day reported open-market sales of 15,000 shares of Common Stock. The trades took place on June 1, 2026 in three transactions at prices around $131 per share. Footnotes state these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the timing was scheduled in advance rather than discretionary.
GILD — Rule 144 notice for proposed resale of restricted shares. The filing lists 35,000 shares of Common stock associated with Morgan Stanley Smith Barney LLC as broker/dealer. The record shows prior dispositions of 10,000 shares on 03/27/2026 and 10,000 shares on 04/28/2026 with the reported proceeds for each transaction.
Gilead Sciences, Inc. entered into an Eleventh Supplemental Indenture to support a new multi-tranche senior notes offering under its existing base indenture. The company issued 4.250% Senior Notes due 2028 with an aggregate principal amount of $500,000,000 and 4.400% Senior Notes due 2029 with an aggregate principal amount of $1,000,000,000.
It also issued 4.600% Senior Notes due 2031 with an aggregate principal amount of $1,000,000,000 and 4.900% Senior Notes due 2034 with an aggregate principal amount of $500,000,000. These notes were sold in a public offering from an effective Form S-3 shelf, with semi-annual interest payments until their respective maturities. Gilead plans to use the net proceeds for general corporate purposes, including potential acquisitions, investments, strategic transactions or other business opportunities.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at an average price of $132.27 per share. After this transaction, he directly holds 173,191 shares of Gilead common stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the trade was scheduled in advance rather than timed discretionarily.
Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.
That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.